Based on this phenomenon, it is rational to utilize HLA-A*02–restricted PRAME-peptide to generate PRAME CTLs from healthy donors or patients, which could release IFNγ and lyse PRAME peptide–expressing cells in an MHC-restricted manner and pave the way for AML immunotherapy (33). This evidence concerns the gene HLA-A and acute myeloid leukemia.